Intra-Cellular Ther (ITCI) 47.85 $ITCI
These Drugs Could Deliver $5 Billion (or More) in Annual Sales
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Nov 01, 8:41AM CST
Photo by Images_of_Money / Flickr Creative Commons Every investor who puts some money to work in the biotech or pharmaceutical space dreams about owning a company with a drug that goes on to generate billions in worldwide sales, as companies that...
NVO: 53.18 (+0.12), ITCI: 47.85 (-3.59), CELG: 122.71 (-2.22)
Should You Buy Intra-Cellular Therapies (ITCI) Ahead of Earnings?
Zacks Equity Research - Zacks Investment Research - Fri Oct 30, 7:50AM CDT
Intra-Cellular Therapies is poised to beat at earnings season given its favorable Zacks Rank and an ESP in positive territory.
ITCI: 47.85 (-3.59)
6 Billion Reasons This Biotech Is a Buy
Brian Feroldi, The Motley Fool - Motley Fool - Fri Oct 30, 7:03AM CDT
Image by Tax Credits, Flickr Creative Commons. Investing in clinical-stage biopharmaceutical companies isn't for the faint of heart. Companies in this early stage have the odds stacked against them, as only one in every 5,000 to 10,000 experimental...
ITCI: 47.85 (-3.59), BMY: 65.95 (-1.36)
Intra-Cellular Therapies to Host Third Quarter 2015 Financial Results Conference Call and Webcast
GlobeNewswire - Thu Oct 29, 7:00AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:00 a.m. Eastern Time on Thursday, November 5, 2015, to discuss financial results for the third quarter ended September 30, 2015, and provide a business update.
ITCI: 47.85 (-3.59)
Can Varian (VAR) Earnings Surprise Estimates in Q4?
Zacks Equity Research - Zacks Investment Research - Mon Oct 26, 2:20PM CDT
Varian Medical Systems (VAR) is set to report its fourth-quarter fiscal 2015 earnings results on Oct 28, following the close of regular trading
AMSG: 70.09 (-1.42), AQXP: 15.29 (+0.73), VAR: 78.53 (-0.02), ITCI: 47.85 (-3.59)
Qiagen Poised on Molecular Diagnostics, International Business
Zacks Equity Research - Zacks Investment Research - Mon Oct 12, 1:50PM CDT
On Oct 9, 2015, we issued an updated research report on Qiagen N.V. (QGEN).
DVAX: 22.71 (+0.63), ITCI: 47.85 (-3.59), QGEN: 24.17 (+0.10), ANIK: 38.52 (-0.55)
Why Shares of Intra-Cellular Therapies Inc Skyrocketed in September
Brian Feroldi, The Motley Fool - Motley Fool - Sat Oct 10, 7:01AM CDT
Intra-Cellular Therapies treated its investors to a great month, as shares of the biotech stock shot higher after the company released great clinical news. Get all the details in the following slideshow. The next billion-dollar iSecret The...
ITCI: 47.85 (-3.59)
Covered Call Alerts For Chesapeake Energy, Joy Global, Intra-Cellular Therapies, CyberArk Software and Arrowhead Research Released By InvestorsObserver
PR Newswire - Fri Oct 09, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CHK, JOY, ITCI, CYBR and ARWR.
JOY: 17.18 (+0.37), ARWR: 5.15 (-0.04), CYBR: 49.64 (+1.36), CHK: 7.13 (+0.19), ITCI: 47.85 (-3.59)
Intra-Cellular Therapies to Present at the CNS Summit 2015 Conference
GlobeNewswire - Fri Oct 09, 7:00AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced today that top-line data from the Phase 3 ITI-007-301 clinical trial will be presented at the CNS Summit 'Shaping the future of Drug Development' 2015 Conference being held in Boca Raton, Florida October 8-11, 2015. A poster presentation of the data is scheduled for Friday, October 9, 2015 and an oral presentation by Kimberly Vanover, Ph.D., Vice President of Clinical Development is scheduled for Sunday, October 11, 2015. The presentations will feature the previously announced top-line data from ITI-007-301, the Company's first Phase 3 clinical trial in patients with schizophrenia.
ITCI: 47.85 (-3.59)
3 Reasons Momentum Stock Investors Will Love Intra-Cellular Therapies (ITCI)
Zacks Equity Research - Zacks Investment Research - Thu Oct 01, 7:48AM CDT
Intra-Cellular Therapies is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions
ITCI: 47.85 (-3.59)
Intra-Cellular Therapies raises USD345m from public offering including exercise of underwriters' option
M2 - Tue Sep 29, 5:07AM CDT
Biopharmaceutical company Intra-Cellular Therapies (NasdaqGS:ITCI) disclosed on Monday that it has completed a public offering of 6,900,000 shares of its common stock.
ITCI: 47.85 (-3.59)
Intra-Cellular Therapies Announces Closing of $345 Million Public Offering Including Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Mon Sep 28, 3:05PM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced the completion of its previously announced underwritten public offering of 6,900,000 shares of its common stock at a public offering price of $43.50 per share. In addition, the underwriters have exercised an option to purchase an additional 1,035,000 shares of common stock at the public offering price, less the underwriting discounts and commissions.
ITCI: 47.85 (-3.59)
The Zacks Analyst Blog Highlights: Juno, Amgen, Gilead, Intra-Cellular and TRACONThe Zacks Analyst Blog Highlights: Juno, Amgen, Gilead, Intra-Cellular and TRACON
Zacks Equity Research - Zacks Investment Research - Thu Sep 24, 8:30AM CDT
The Zacks Analyst Blog Highlights: Juno, Amgen, Gilead, Intra-Cellular and TRACON
GILD: 108.13 (-1.08), AMGN: 158.18 (-2.40), ITCI: 47.85 (-3.59), JUNO: 51.76 (+0.37), TCON: 10.50 (+0.07)
Intra-Cellular Therapies to Present at the Ladenburg Thalmann 2015 Healthcare Conference
GlobeNewswire - Thu Sep 24, 6:59AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, will present at the Ladenburg Thalmann 2015 Healthcare Conference 2015 in New York, NY. The presentation is scheduled for Tuesday, September 29, 2015 at 11:30 AM EDT.
ITCI: 47.85 (-3.59)
Biotech Stock Roundup: Clinton's Tweet Shakes Biotech Stocks, Amgen In Pipeline-Boosting Deals
Arpita Dutt - Zacks Investment Research - Wed Sep 23, 11:37AM CDT
Hillary Clinton's tweet about skyrocketing drug prices triggered a sell-off in the biotech sector reflecting concerns regarding the implementation of price control measures.
BIIB: 290.51 (-3.21), GILD: 108.13 (-1.08), AMGN: 158.18 (-2.40), JUNO: 51.76 (+0.37), ITCI: 47.85 (-3.59), TCON: 10.50 (+0.07), REGN: 557.39 (-2.63)
Intra-Cellular Therapies (ITCI) Stock Climbs After Pricing 6.9 Million Share Offering
at The Street - Wed Sep 23, 10:36AM CDT
Intra-Cellular Therapies (ITCI) are rising after the company priced its offering of 6.9 million shares at $43.50 per share.
ITCI: 47.85 (-3.59)
Intra-Cellular Therapies prices public offering at USD43.50 per share
M2 - Wed Sep 23, 3:07AM CDT
Biopharmaceutical company Intra-Cellular Therapies (NasdaqGS:ITCI) stated on Tuesday that it has priced an underwritten public offering of 6,900,000 shares of its common stock.
ITCI: 47.85 (-3.59)
Global Autism Pipeline Review, H2 2015 - 19 Companies & 31 Drug Profiles
M2 - Wed Sep 23, 3:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tf7gbm/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - BioCrea GmbH - BrainStorm Cell Therapeutics Inc. - Cellceutix Corporation - Confluence Pharmaceuticals LLC - Curemark, LLC - Egenix, Inc. - F. Hoffmann-La Roche Ltd. - Heptares Therapeutics Limited - Intra-Cellular Therapies, Inc. - MedDay - Merz Pharma GmbH & Co. KgaA - Mnemosyne Pharmaceuticals, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Retrophin Inc. - Reviva Pharmaceuticals Inc. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. Drug Profiles - (dextromethorphan hydrobromide quinidine sulfate) - acamprosate calcium - ADX-71441 - ADX-88178 - aripiprazole - carbetocin - CM-AT - CN-2097 - Drug for Autism - HTL-14242 - ITI-007 - KM-391 - lurasidone hydrochloride - MD-1103 - memantine hydrochloride - oxytocin - RG-7314 - RO-5285119 - RP-5063 - Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism - Small Molecule to Modulate GABRA5 Receptor for CNS Disorders - Small Molecule to Target GPR63 for Autism - Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Small Molecules to Antagonize NMDA2A for Central Nervous System Disorders - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Small Molecules to Inhibit Translation Initiation Factor-4E for Cancer and Autism - Small Molecules to Target Oxytocin for Autism and Anxiety Disorders - Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Autism and Bronchopulmonary Dysplasia - Stem Cell Therapy for Neurodegenerative Disorders - suramin hexasodium - VU-0410120 For more information visit http://www.researchandmarkets.com/research/tf...m_pipeline
RTRX: 19.13 (+0.05), ITCI: 47.85 (-3.59), BCLI: 2.78 (+0.01), OMER: 12.53 (-0.23)
Intra-Cellular Therapies Prices $300 Million Public Offering of Common Stock
GlobeNewswire - Tue Sep 22, 5:40PM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 6,900,000 shares of its common stock at a public offering price of $43.50 per share. All of the shares in the offering will be sold by Intra-Cellular Therapies. Net proceeds to Intra-Cellular Therapies from the sale of the shares, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $284.7 million.
ITCI: 47.85 (-3.59)
Intra-Cellular Therapies to issue USD300m common stock in public offering
M2 - Tue Sep 22, 3:01AM CDT
Biopharmaceutical company Intra-Cellular Therapies (NasdaqGS:ITCI) revealed on Monday that it has commenced the public offering of USD300m of shares of its common stock.
ITCI: 47.85 (-3.59)
These Drugs Could Deliver $5 Billion (or More) in Annual Sales
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Nov 01, 8:41AM CST
Photo by Images_of_Money / Flickr Creative Commons Every investor who puts some money to work in the biotech or pharmaceutical space dreams about owning a company with a drug that goes on to generate billions in worldwide sales, as companies that...
NVO: 53.18 (+0.12), ITCI: 47.85 (-3.59), CELG: 122.71 (-2.22)
Should You Buy Intra-Cellular Therapies (ITCI) Ahead of Earnings?
Zacks Equity Research - Zacks Investment Research - Fri Oct 30, 7:50AM CDT
Intra-Cellular Therapies is poised to beat at earnings season given its favorable Zacks Rank and an ESP in positive territory.
ITCI: 47.85 (-3.59)
6 Billion Reasons This Biotech Is a Buy
Brian Feroldi, The Motley Fool - Motley Fool - Fri Oct 30, 7:03AM CDT
Image by Tax Credits, Flickr Creative Commons. Investing in clinical-stage biopharmaceutical companies isn't for the faint of heart. Companies in this early stage have the odds stacked against them, as only one in every 5,000 to 10,000 experimental...
ITCI: 47.85 (-3.59), BMY: 65.95 (-1.36)
Intra-Cellular Therapies to Host Third Quarter 2015 Financial Results Conference Call and Webcast
GlobeNewswire - Thu Oct 29, 7:00AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:00 a.m. Eastern Time on Thursday, November 5, 2015, to discuss financial results for the third quarter ended September 30, 2015, and provide a business update.
ITCI: 47.85 (-3.59)
Can Varian (VAR) Earnings Surprise Estimates in Q4?
Zacks Equity Research - Zacks Investment Research - Mon Oct 26, 2:20PM CDT
Varian Medical Systems (VAR) is set to report its fourth-quarter fiscal 2015 earnings results on Oct 28, following the close of regular trading
AMSG: 70.09 (-1.42), AQXP: 15.29 (+0.73), VAR: 78.53 (-0.02), ITCI: 47.85 (-3.59)
Qiagen Poised on Molecular Diagnostics, International Business
Zacks Equity Research - Zacks Investment Research - Mon Oct 12, 1:50PM CDT
On Oct 9, 2015, we issued an updated research report on Qiagen N.V. (QGEN).
DVAX: 22.71 (+0.63), ITCI: 47.85 (-3.59), QGEN: 24.17 (+0.10), ANIK: 38.52 (-0.55)
Why Shares of Intra-Cellular Therapies Inc Skyrocketed in September
Brian Feroldi, The Motley Fool - Motley Fool - Sat Oct 10, 7:01AM CDT
Intra-Cellular Therapies treated its investors to a great month, as shares of the biotech stock shot higher after the company released great clinical news. Get all the details in the following slideshow. The next billion-dollar iSecret The...
ITCI: 47.85 (-3.59)
Covered Call Alerts For Chesapeake Energy, Joy Global, Intra-Cellular Therapies, CyberArk Software and Arrowhead Research Released By InvestorsObserver
PR Newswire - Fri Oct 09, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CHK, JOY, ITCI, CYBR and ARWR.
JOY: 17.18 (+0.37), ARWR: 5.15 (-0.04), CYBR: 49.64 (+1.36), CHK: 7.13 (+0.19), ITCI: 47.85 (-3.59)
Intra-Cellular Therapies to Present at the CNS Summit 2015 Conference
GlobeNewswire - Fri Oct 09, 7:00AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, announced today that top-line data from the Phase 3 ITI-007-301 clinical trial will be presented at the CNS Summit 'Shaping the future of Drug Development' 2015 Conference being held in Boca Raton, Florida October 8-11, 2015. A poster presentation of the data is scheduled for Friday, October 9, 2015 and an oral presentation by Kimberly Vanover, Ph.D., Vice President of Clinical Development is scheduled for Sunday, October 11, 2015. The presentations will feature the previously announced top-line data from ITI-007-301, the Company's first Phase 3 clinical trial in patients with schizophrenia.
ITCI: 47.85 (-3.59)
3 Reasons Momentum Stock Investors Will Love Intra-Cellular Therapies (ITCI)
Zacks Equity Research - Zacks Investment Research - Thu Oct 01, 7:48AM CDT
Intra-Cellular Therapies is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions
ITCI: 47.85 (-3.59)
Intra-Cellular Therapies raises USD345m from public offering including exercise of underwriters' option
M2 - Tue Sep 29, 5:07AM CDT
Biopharmaceutical company Intra-Cellular Therapies (NasdaqGS:ITCI) disclosed on Monday that it has completed a public offering of 6,900,000 shares of its common stock.
ITCI: 47.85 (-3.59)
Intra-Cellular Therapies Announces Closing of $345 Million Public Offering Including Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Mon Sep 28, 3:05PM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced the completion of its previously announced underwritten public offering of 6,900,000 shares of its common stock at a public offering price of $43.50 per share. In addition, the underwriters have exercised an option to purchase an additional 1,035,000 shares of common stock at the public offering price, less the underwriting discounts and commissions.
ITCI: 47.85 (-3.59)
The Zacks Analyst Blog Highlights: Juno, Amgen, Gilead, Intra-Cellular and TRACONThe Zacks Analyst Blog Highlights: Juno, Amgen, Gilead, Intra-Cellular and TRACON
Zacks Equity Research - Zacks Investment Research - Thu Sep 24, 8:30AM CDT
The Zacks Analyst Blog Highlights: Juno, Amgen, Gilead, Intra-Cellular and TRACON
GILD: 108.13 (-1.08), AMGN: 158.18 (-2.40), ITCI: 47.85 (-3.59), JUNO: 51.76 (+0.37), TCON: 10.50 (+0.07)
Intra-Cellular Therapies to Present at the Ladenburg Thalmann 2015 Healthcare Conference
GlobeNewswire - Thu Sep 24, 6:59AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, will present at the Ladenburg Thalmann 2015 Healthcare Conference 2015 in New York, NY. The presentation is scheduled for Tuesday, September 29, 2015 at 11:30 AM EDT.
ITCI: 47.85 (-3.59)
Biotech Stock Roundup: Clinton's Tweet Shakes Biotech Stocks, Amgen In Pipeline-Boosting Deals
Arpita Dutt - Zacks Investment Research - Wed Sep 23, 11:37AM CDT
Hillary Clinton's tweet about skyrocketing drug prices triggered a sell-off in the biotech sector reflecting concerns regarding the implementation of price control measures.
BIIB: 290.51 (-3.21), GILD: 108.13 (-1.08), AMGN: 158.18 (-2.40), JUNO: 51.76 (+0.37), ITCI: 47.85 (-3.59), TCON: 10.50 (+0.07), REGN: 557.39 (-2.63)
Intra-Cellular Therapies (ITCI) Stock Climbs After Pricing 6.9 Million Share Offering
at The Street - Wed Sep 23, 10:36AM CDT
Intra-Cellular Therapies (ITCI) are rising after the company priced its offering of 6.9 million shares at $43.50 per share.
ITCI: 47.85 (-3.59)
Intra-Cellular Therapies prices public offering at USD43.50 per share
M2 - Wed Sep 23, 3:07AM CDT
Biopharmaceutical company Intra-Cellular Therapies (NasdaqGS:ITCI) stated on Tuesday that it has priced an underwritten public offering of 6,900,000 shares of its common stock.
ITCI: 47.85 (-3.59)
Global Autism Pipeline Review, H2 2015 - 19 Companies & 31 Drug Profiles
M2 - Wed Sep 23, 3:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tf7gbm/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - BioCrea GmbH - BrainStorm Cell Therapeutics Inc. - Cellceutix Corporation - Confluence Pharmaceuticals LLC - Curemark, LLC - Egenix, Inc. - F. Hoffmann-La Roche Ltd. - Heptares Therapeutics Limited - Intra-Cellular Therapies, Inc. - MedDay - Merz Pharma GmbH & Co. KgaA - Mnemosyne Pharmaceuticals, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Retrophin Inc. - Reviva Pharmaceuticals Inc. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. Drug Profiles - (dextromethorphan hydrobromide quinidine sulfate) - acamprosate calcium - ADX-71441 - ADX-88178 - aripiprazole - carbetocin - CM-AT - CN-2097 - Drug for Autism - HTL-14242 - ITI-007 - KM-391 - lurasidone hydrochloride - MD-1103 - memantine hydrochloride - oxytocin - RG-7314 - RO-5285119 - RP-5063 - Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism - Small Molecule to Modulate GABRA5 Receptor for CNS Disorders - Small Molecule to Target GPR63 for Autism - Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Small Molecules to Antagonize NMDA2A for Central Nervous System Disorders - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Small Molecules to Inhibit Translation Initiation Factor-4E for Cancer and Autism - Small Molecules to Target Oxytocin for Autism and Anxiety Disorders - Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Autism and Bronchopulmonary Dysplasia - Stem Cell Therapy for Neurodegenerative Disorders - suramin hexasodium - VU-0410120 For more information visit http://www.researchandmarkets.com/research/tf...m_pipeline
RTRX: 19.13 (+0.05), ITCI: 47.85 (-3.59), BCLI: 2.78 (+0.01), OMER: 12.53 (-0.23)
Intra-Cellular Therapies Prices $300 Million Public Offering of Common Stock
GlobeNewswire - Tue Sep 22, 5:40PM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 6,900,000 shares of its common stock at a public offering price of $43.50 per share. All of the shares in the offering will be sold by Intra-Cellular Therapies. Net proceeds to Intra-Cellular Therapies from the sale of the shares, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $284.7 million.
ITCI: 47.85 (-3.59)
Intra-Cellular Therapies to issue USD300m common stock in public offering
M2 - Tue Sep 22, 3:01AM CDT
Biopharmaceutical company Intra-Cellular Therapies (NasdaqGS:ITCI) revealed on Monday that it has commenced the public offering of USD300m of shares of its common stock.
ITCI: 47.85 (-3.59)
